| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:QD325
CAS:2132410-88-7
Package:50mg/RMB 13800;25mg/RMB 10600;100mg/RMB 17500
|
5,8-Quinazolinedione, 6-([1,1'-biphenyl]-4-ylamino)- manufacturers
- QD325
-
- $1980.00 / 50mg
-
2025-08-21
- CAS:2132410-88-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 5,8-Quinazolinedione, 6-([1,1'-biphenyl]-4-ylamino)- Basic information |
| | 5,8-Quinazolinedione, 6-([1,1'-biphenyl]-4-ylamino)- Chemical Properties |
| Boiling point | 551.0±50.0 °C(Predicted) | | density | 1.379±0.06 g/cm3(Predicted) | | pka | -2.65±0.20(Predicted) |
| | 5,8-Quinazolinedione, 6-([1,1'-biphenyl]-4-ylamino)- Usage And Synthesis |
| Description | QD325 is a potent redox modulator for the Treatment of Pancreatic Ductal Adenocarcinoma. QD325 can induce substantial reactive oxygen species (ROS) in PDAC cells. Nascent RNA sequencing following treatments with QD325 revealed induction of stress responses in nucleus, endoplasmic reticulum, and mitochondria of pancreatic cancer cells. Furthermore, QD325 induced Nrf2-mediated oxidative stress and unfolded protein responses as demonstrated by dose dependent increases in RNA synthesis of representative genes such as NQO1, HMOX1, DDIT3 and HSPA5. QD325 is as a new therapeutic in the treatment of PDAC. |
| | 5,8-Quinazolinedione, 6-([1,1'-biphenyl]-4-ylamino)- Preparation Products And Raw materials |
|